CSL (CSL.AX) reported revenue of $7.30B in Q2 2026.
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
CSL (CSL.AX) reported revenue of $7.30B in Q2 2026.
H2 2016-H1 2026
H2 2016-H1 2026
CSLAustralian plasma and vaccines group. Seqirus is the number-two global flu manufacturer (cell-based Flucelvax, adjuvanted Fluad) and a pandemic-flu contract holder.
CSL (CSL.AX) is a Biotechnology company. Australian plasma and vaccines group. Seqirus is the number-two global flu manufacturer (cell-based Flucelvax, adjuvanted Fluad) and a pandemic-flu contract holder. It was founded in 1916, is headquartered in Melbourne, Australia and employs about 32,000 people.
Track CSL's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 19, 2026.
Sterling groups CSL in the Vaccines sector, alongside GSK (GSK), Pfizer (PFE), Merck & Co. (MRK), Sanofi (SNY), Moderna (MRNA) and BioNTech (BNTX).
If you are researching CSL, also look at GSK (GSK), Pfizer (PFE) and Merck & Co. (MRK). You can compare all of them side by side or browse the full Vaccines sector on Sterling.